Get started
Author

Changying Li

Rebalancing liver-infiltrating CCR3+ and CD206+ monocytes improves diet-induced NAFLD
2023 · Guangyong Sun, Yaning Wang, et al. · Cell Reports · 21
PDF
Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease
2023 · Huan Wang, Yushang Zhao, et al. · JHEP Reports · 17
PDF
Hepcidin inhibits hepatocyte apoptosis through the PERK pathway in acute liver injury and fibrosis
2024 · Changying Li, Guojin Pang, et al. · Hepatology Communications · 6
Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC
2026 · Xin Xu, Xin Chen, et al. · Nature Communications · 5
Dibenzocyclooctyne linked lysine-cyclodextrin for efficient intranucleus delivery of proteins
2022 · Zhiying Zeng, Changying Li, et al. · Journal of Controlled Release · 4
Author Correction: Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC
2026 · Xin Xu, Xin Chen, et al. · Nature Communications
PDF
Supplemental Figure 5 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 3 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 1 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 8 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Table 2 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 2 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 4 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 9 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 10 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 7 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Figure 6 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Supplemental Table 1 from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Data from Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2026 · Changying Li, Xuran Zhao, et al.
Targeting the ATM–TGS1–BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma
2025 · Changying Li, Xuran Zhao, et al. · Cancer Research
PAK1 inhibition synergistically enhances the anti-tumor efficacy of PARP inhibitors in ovarian cancers
2025 · Changying Li, Xinyan Li, et al. · Genes & Diseases
Works count: 21
Citation count: 53
H-index: 4
I10-index: 2
Year
Topic
Type